Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 24;22(1):45.
doi: 10.1186/s10194-021-01250-6.

Burden of migraine and unmet needs from the patients' perspective: a survey across 11 specialized headache clinics in Korea

Byung-Kun Kim  1 , Min Kyung Chu  2 , Soo Jin Yu  3 , Grazia Dell'Agnello  4 , Jeong Hee Han  3 , Soo-Jin Cho  5
Affiliations

Burden of migraine and unmet needs from the patients' perspective: a survey across 11 specialized headache clinics in Korea

Byung-Kun Kim et al. J Headache Pain. .

Erratum in

Abstract

Background: Migraine is a neurological, primary headache disorder affecting more than 1 billion people worldwide, with a multi-faceted burden that can significantly impact the everyday life of a patient, both during and between attacks. However, studies on patient awareness, burden, and clinical management of migraine in Korea are limited and outdated. The aim of this study was to comprehensively investigate the current difficulties and unmet needs that Korean patients with migraine encounter from their perspective.

Methods: A total of 207 patients with episodic or chronic migraine aged between 15 and 76 years, completed a survey designed to cover the following topics: diagnosis, understanding of the disease, treatment experience, disability, and quality of life. Patients were recruited by their neurologists from 11 specialized headache clinics in Korea and completed the survey between 22 July and 19 August 2019. Validated scales such as the Migraine Disability Assessment (MIDAS) questionnaire and Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQv2.1) were used to assess levels of disability and quality of life, respectively, in patients.

Results: On average, it took 10.1 years from onset of symptoms to diagnosis and a mean of 3.9 hospitals were visited for treatment prior to the patient's current hospital. There was a lack of understanding among respondents about migraine, with 55.6% believing that unilateral headache is a unique feature of migraine compared with other headache disorders. On average, high levels of disability and poor quality of life were reported by patients, as assessed by MIDAS and MSQv2.1, respectively, but only 23.7% had regularly taken preventive medication in the past. Overall satisfaction with previous doctor-patient relationships was reported by 29.5% of respondents, and satisfaction with preventive and acute medications by only 40.8% and 27.1% of the respondents, respectively.

Conclusion: Korean patients with migraine experience significant disability and reduced quality of life as a result of the disease and have clear unmet needs in terms of diagnosis, understanding of the disease, and disease management including treatment.

Keywords: Burden; Diagnosis; Disability; Korea; MIDAS; MSQv2.1; Migraine; Patient survey; Treatment.

PubMed Disclaimer

Conflict of interest statement

BKK has received consulting fees and honoraria from the Center for New Health Technology Assessment, National Pension Service, Eli Lilly, Allergan, Teva, Lundbeck, Novartis, Sanofi Korea, SK Pharm, Yuyu Pharm, and Ildong Pharm during the last two years. MKC was involved as a site investigator for a multicenter trial sponsored by Otsuka Korea, Allergan, Ildong Pharmaceutical Co., LTD, Novartis International AG, and Eli Lilly and Company. He has worked as an advisory member for Teva, and has received lecture honoraria from Allergan Korea, Handok-Teva and Yuyu Pharmaceutical Company. SJY is a full-time employee of Eli Lilly and Company. GDA is a full-time employee and a minor stockholder of Eli Lilly and Company. JHH is a full-time employee of Eli Lilly and Company. SJC was involved as a site investigator for a multicenter trial sponsored by Otsuka Korea, Allergan, Ildong Pharmaceutical Co., LTD, Novartis International AG, Eli Lilly and Company, Parexel Korea Co., Ltd., and has received lecture honoraria from Allergan Korea, WhanIn Pharm Co., LTD, Handok-Teva, Yuyu Pharmaceutical Company, and SK Chemicals.

Figures

Fig. 1
Fig. 1
Knowledge about migraine. Results for knowledge of migraine are presented for each age group and for overall respondents, the latter inclusive of all age groups. Results are presented as percentage of respondents. N = Number of patients
Fig. 2
Fig. 2
Migraine-related disability, quality of life, and pain severity. Results for MIDAS, MSQ total, MSQ RR, and pain severity are presented for each age group and for overall respondents, the latter inclusive of all age groups. Results are presented as mean score (SE). MIDAS = Migraine Disability Assessment; MSQ = Migraine-Specific Quality of Life Questionnaire; RR = Role Function-Restrictive; N = Number of patients; SE = Standard Error
Fig. 3
Fig. 3
Past experience with preventive medication for migraine. Results for (a) prior regular use of preventive medication, (b) satisfaction with preventive medication, burden of cost, and withdrawal due to side effects, and (c) side effects experienced by those who withdrew are presented for each age group (and MIDAS grade group in (A)) and for overall respondents, the latter inclusive of all age groups. Results are presented as mean percentage of respondents. MIDAS = Migraine Disability Assessment; GI = Gastro-intestinal; N = Number of patients. * Respondents who did not take preventive medication regularly only took it when they were experiencing a headache. Those who took preventive medication regularly did so even in the absence of a headache
See this image and copyright information in PMC

References

    1. Wijeratne T, Grisold W, Dodick D, Carroll W. World brain day 2019: migraine, the painful truth. Lancet Neurol. 2019;18(10):914. doi: 10.1016/S1474-4422(19)30281-9. - DOI - PubMed
    1. Woldeamanuel YW, Cowan RP. Migraine affects 1 in 10 people worldwide featuring recent rise: a systematic review and meta-analysis of community-based studies involving 6 million participants. J Neurol Sci. 2017;372:307–315. doi: 10.1016/j.jns.2016.11.071. - DOI - PubMed
    1. GBD Disease and injury incidence and prevalence collaborators (2018) global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2017;392(10159):1789–1858. - PMC - PubMed
    1. Steiner TJ, Stovner LJ, Vos T, Jensen R, Katsarava Z. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018;19(1):17. doi: 10.1186/s10194-018-0846-2. - DOI - PMC - PubMed
    1. Steiner TJ, Stovner LJ, Katsarava Z, Lainez JM, Lampl C, Lanteri-Minet M, et al. The impact of headache in Europe: principal results of the Eurolight project. J Headache Pain. 2014;15(1):31. doi: 10.1186/1129-2377-15-31. - DOI - PMC - PubMed